| Literature DB >> 33886137 |
Marat Fudim1, Piotr P Ponikowski1, Daniel Burkhoff1, Mark E Dunlap1, Paul A Sobotka1, Jeroen Molinger1, Manesh R Patel1, G Michael Felker1, Adrian F Hernandez1, Sheldon E Litwin1, Barry A Borlaug1, Anisha Bapna1, Horst Sievert1, Vivek Y Reddy1, Zoar J Engelman1, Sanjiv J Shah1.
Abstract
Volume recruitment from the splanchnic compartment is an important physiological response to stressors such as physical activity and blood loss. In the setting of heart failure (HF), excess fluid redistribution from this compartment leads to increased cardiac filling pressures with limitation in exercise capacity. Recent evidence suggests that blocking neural activity of the greater splanchnic nerve (GSN) could have significant benefits in some patients with HF by reducing cardiac filling pressures and improving exercise capacity. However, to date the long-term safety of splanchnic nerve modulation (SNM) in the setting of HF is unknown. SNM is currently used in clinical practice to alleviate some forms of chronic abdominal pain. A systematic review of the series where permanent SNM was used as a treatment for chronic abdominal pain indicates that permanent SNM is well tolerated, with side-effects limited to transient diarrhoea or abdominal colic and transient hypotension. The pathophysiological role of the GSN in volume redistribution, the encouraging findings of acute and chronic pilot SNM studies and the safety profile from permanent SNM for pain provides a strong basis for continued efforts to study this therapeutic target in HF.Entities:
Keywords: Adverse effects; Splanchnic vasoconstriction; Sympathetic nervous system
Mesh:
Year: 2021 PMID: 33886137 PMCID: PMC8298285 DOI: 10.1002/ejhf.2196
Source DB: PubMed Journal: Eur J Heart Fail ISSN: 1388-9842 Impact factor: 17.349